Ikarian Capital’s InMed Pharmaceuticals INM Stock Holding History

Ikarian Capital’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$380K	Buy	+245,025	New	+$271K	0.04%	131

Other funds holding INM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Squadron Capital Management Westmont, Illinois $322M AUM

Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Ikarian Capital's INM Position: Q2 2026 in Review

Ikarian Capital opened a new position in InMed Pharmaceuticals (INM) in Q2 2026: 245,025 shares worth $380K. The stake represents 0.04% of the portfolio and ranks #131 among its holdings.

20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

Ikarian Capital held 245,025 shares of InMed Pharmaceuticals worth $380K as of Q2 2026.
InMed Pharmaceuticals was a new Ikarian Capital position in Q2 2026.
InMed Pharmaceuticals made up 0.04% of Ikarian Capital's portfolio in Q2 2026, its #131 holding.
20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.